[HTML][HTML] Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
Background Patients with cancer‐associated venous thromboembolism (VTE) are
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …
Extended anticoagulation treatment for cancer-associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
F Moik, M Colling, I Pabinger, C Ay, I Mahé… - Journal of Thrombosis …, 2021 - elibrary.ru
Florian Moik: no potential conflict of interest. Meaghan Colling: no potential conflict of
interest. Isabelle Mahé: grants, honoraria, and personal fees for lectures and participation on …
interest. Isabelle Mahé: grants, honoraria, and personal fees for lectures and participation on …
Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
F Moik, M Colling, I Mahé… - … of Thrombosis and …, 2022 - Wiley Online Library
Background Patients with cancer‐associated venous thromboembolism (VTE) are
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …
Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
F Moik, M Colling, I Mahé, L Jara‐Palomares… - Journal of Thrombosis …, 2022 - jthjournal.org
Background Patients with cancer‐associated venous thromboembolism (VTE) are
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …
Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review
F Moik, M Colling, I Mahé… - … of thrombosis and …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Patients with cancer-associated venous thromboembolism (VTE) are
recommended to receive treatment with therapeutic anticoagulation for at least 3-6 months …
recommended to receive treatment with therapeutic anticoagulation for at least 3-6 months …
[HTML][HTML] Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
F Moik, M Colling, I Mahé… - … of Thrombosis and …, 2022 - ncbi.nlm.nih.gov
Background Patients with cancer‐associated venous thromboembolism (VTE) are
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …
Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review.
F Moik, M Colling, I Mahé… - … of Thrombosis and …, 2021 - europepmc.org
Background Patients with cancer-associated venous thromboembolism (VTE) are
recommended to receive treatment with therapeutic anticoagulation for at least 3-6 months …
recommended to receive treatment with therapeutic anticoagulation for at least 3-6 months …